Prior CLL Foreshadows Worse Overall Survival than NHL with Subsequent Malignant Melanoma or Merkel Cell Carcinoma

Share this content:

(ChemotherapyAdvisor) – Patients who had chronic lymphocytic leukemia (CLL) prior to a diagnosis of malignant melanoma or Merkel cell carcinoma had significantly worse overall survival (OS) as well as cause-specific survival from the two skin cancers than those with non-Hodgkin's lymphoma (NHL), a study published in the Journal of Clinical Oncology online February 13 has found.

The investigators identified patients in the Surveillance, Epidemiology, and End Results (SEER) database from 1990 to 2006 with malignant melanoma (n=212,245) or Merkel cell carcinoma (n=3,613) and analyzed the effects of a history of CLL or NHL on OS and cause-specific survival after the skin-cancer diagnosis. Prior CLL/NHL was determined to have occurred in 1,246 patients with malignant melanoma and 90 with Merkel cell carcinoma.

Compared with patients with malignant melanoma or Merkel cell carcinoma without CLL/NHL, those with malignant melanoma and a history of CLL/NHL had worse-than-expected OS as measured by standardized mortality ratio: CLL, 2.6 and NHL, 2.3. Cause-specific survival for malignant melanoma was also worse than expected: CLL, 2.8; NHL, 2.1. For patients with Merkel cell carcinoma, OS ratio was 3.1 for CLL and 1.9 for NHL. Cause-specific survival was 3.8 for CLL and no difference was observed for NHL, 0.9.


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs